Research programme: antibody drug conjugates - PharmAbcine
Alternative Names: PMC-005BLatest Information Update: 09 Dec 2021
At a glance
- Originator PharmAbcine
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Dec 2021 Preclinical trials in Solid tumours in South Korea (Parenteral), prior to December 2021 (PharmAbcine pipeline, December 2021)
- 10 Oct 2019 Early research in Solid tumours in South Korea (Parenteral) (PharmAbcine pipeline, October 2019)